Published on December 9, 2009 at 11:06 PM
- Roche to Present new Results That Could Offer a Better Future to Women With Early and Very Advanced
Breast Cancer, at the CTRC-AACR San Antonio Breast
Cancer Symposium
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new 5 year follow-up data from two pivotal studies with Herceptin(R) (trastuzumab) in early breast cancer; key results from a study of Avastin(R) (bevacizumab) in the second-line treatment of advanced breast cancer and strong data on the use of trastuzumab-DM1 (T-DM1), the first antibody-drug conjugate in development for very advanced HER2-positive breast cancer, will all be presented during the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) from 9 to 13 December 2009.
"Breast cancer is the most common cancer among women worldwide with more than one million new cases diagnosed every year and nearly 400,000 deaths, so it is vital that we continue to provide more treatment options," said William M. Burns, CEO of Roche Pharma. "The much anticipated data on Herceptin, Avastin and the investigational drug T-DM1 will be welcomed by physicians treating women with early and very advanced stages of breast cancer as it will offer them more choices for fighting this devastating disease."
Source: ROCHE
c1cfbc50-f6f7-46e8-84f0-c19f11317469|0|.0
Posted in: Drug Trial News | Women's Health News
Tags: Antibody, Avastin, Bevacizumab, Breast Cancer, Cancer, Carboplatin, Chemotherapy, Cyclophosphamide, Diabetes, Doxorubicin, Metabolism, Oncology